Skip to main content

Table 2 Patients’ characteristics, tumor type and ICI treatments

From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

Baseline CharacteristicsHIV (N = 21)HBV/HCV (N = 34)
Age – Median (range)62 (29–85)62 (29–79)
Sex (% Male)52%71%
Race
 (White %)3325
 (African American %)6750
 (Asian%)012
Tumor types
 Non-small cell lung cancer (NSCLC)1210
 Adenocarcinoma85
 Squamous21
 Non specified24
Anal squamous cell carcinoma22
Hodgkin’s lymphoma (HD)20
Head and neck squamous cell carcinoma (H&N)11
Colorectal carcinoma (CRC)10
Burkitt lymphoma10
Renal clear cell carcinoma (RCC)13
Hepatocellular carcinoma (HCC)116
Small cell lung cancer (SCLC)01
Gastric cancer01
ICI therapy type
Anti-PD-(L)1 monotherapy1630
Anti-PD-(L)1 in combination with anti-CTLA-401
Anti-PD-(L)1 in combination with chemotherapy53